Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Muscle Wasting Disorders Market Predicted to Reach USD 45.4 Billion by 2031, Garnering 15.1% CAGR: TMR Report

TMR_Logo_Logo

News provided by

Transparency Market Research

Oct 30, 2023, 11:30 ET

Share this article

Share toX

Share this article

Share toX

Research and development advances and supportive regulatory environments contribute to muscle wasting disorder demand

WILMINGTON, Del., Oct. 30, 2023 /PRNewswire/ -- The muscle wasting disorders market generated revenues worth US$ 12.7 billion in 2022. The market is predicted to reach US$ 45.4 billion in 2031. Between 2023 and 2031, the market is expected to register a growth rate of 15.1%.

Many diseases and conditions cause muscle wasting and weakness, like aging, cancer, sepsis, cachexia, denervation, inactivity, HIV-acquired immunity syndrome (AIDS), burns, chronic kidney or heart failure, unloading/microgravity, and muscular dystrophies.

Various illnesses and diseases can cause muscle wasting. A study conducted by Trusted Source in 2017 concluded that cancer, heart failure, and sepsis have a worse prognosis when muscle wasting is present. Muscle wasting refers to the gradual loss of muscle tissue. In addition to ALS, muscular dystrophy, and MS, it can also be caused by other medical conditions.

Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=39452

Muscle Wasting Disorders Market Report Scope:

Report Coverage

Details 

Forecast Period 

2023-2031

Base Year 

2017-2021

Size in 2022

US$ 12.7 Bn

Forecast (Value) in 2031

More than US$ 45.4 Bn

Growth Rate (CAGR)

15.1 %

No. of Pages

186 Pages

Segments covered

Type, Treatment Type, End-user

Key Findings of the Market Report

  • The use of pharmaceutical interventions represents yet another potential pathway for progress.
  • Based on treatment type, medication type is expected to lead the market.
  • Among the end-user segments, the hospital segment is expected to increase demand for muscle wasting disorder.
  • Between 2023 and 2031, North America is expected to dominate sales.
  • Physiological atrophy is expected to dominate the market for muscle wasting disorders.

Market Trends for Muscle Wasting Disorders

  • Regulatory agencies are increasingly recognizing muscle wasting disorders, and promising therapies are receiving incentives and fast-track designations. The investment in this area is therefore encouraged by pharmaceutical companies.
  • In recent years, many individuals worldwide have been affected by muscle-wasting disorders, including muscular dystrophy and amyotrophic lateral sclerosis (ALS). As the population ages and awareness rises, this trend will likely continue.
  • New treatment options and therapies are being developed to treat muscle wasting disorders. Several advanced approaches are being explored, including gene therapy, stem cell therapy, and others. Various therapeutic approaches are proposed to slow or even reverse the progression of these disorders.
  • Muscle wasting disorders are becoming more common as new treatments are approved. A physical therapist and pharmaceuticals or medical devices may be used as a treatment.
  • Pharmaceutical companies actively developed drugs and biologics for the treatment of muscle wasting. Some companies that work on muscle atrophy pathways are researching small molecules and biologics.
  • Researchers are discovering new therapeutic targets and potential treatments for muscle atrophy based on molecular and genetic mechanisms. As a result, innovative therapies and pharmaceuticals are encouraged to be developed.

Global Market for Muscle Wasting Disorders Regional Outlook

  • Advanced diagnostics and a high awareness of muscle atrophy in North America are the primary reasons for the market's success. Various governments, including those in the United States, a major regional market, are initiating campaigns to treat patients.
  • As geriatric populations increase, researchers and developers at pharmaceutical companies are increasing their development programs. Chronic diseases are also on the rise. As a result of these factors, the muscle wasting disorder market is growing.
  • Asia Pacific has the largest population and is projected to grow faster due to improved healthcare infrastructure. Increased government funding for research, increased cancer awareness in developing countries, and patient support programs are expected to boost the muscle wasting disorders market in the future.

Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=39452

Global Muscle Wasting Disorders: Key Players

A number of players compete for a limited share of the global muscle-wasting disorders market. An analysis of the global muscle-wasting disorders market has been provided in the report, which includes information such as company overviews, financial profiles, business strategies, product portfolios, and business segments. Key market players in the muscle wasting disorders landscape include:

  • Biogen, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Nippon Shinyaku Co., Ltd. (NS Pharma, Inc.)
  • PTC Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.

Key Developments in the Global Muscle Wasting Disorders Market

  • In June 2023, the U.S. Food and Drug Administration approved Elevidys, a gene therapy for treating children with Duchenne muscular dystrophy (DMD) who are between 4 and 5 years old with a confirmed mutation in the DMD gene and are not unable to undergo treatment due to a pre-existing medical condition.
  • In August 2023, the European Commission extended Evrysdi's EU marketing authorization to include infants born between birth and the age of two months who have one to four copies of the SMN2 gene.

Global Muscle Wasting Disorders Market: Segmentation

  • Type
    • Muscular Dystrophy
      • Duchenne Muscular Dystrophy (DMD)
      • Becker Muscular Dystrophy (BMD)
      • Myotonic Muscular Dystrophy
      • Congenital Muscular Dystrophy
      • Limb-Girdle Muscular Dystrophy
      • Others (Oculopharyngeal Muscular Dystrophy, Emery-Dreifuss Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, etc.)
    • Muscular Atrophy
      • Physiologic Atrophy
      • Pathologic Atrophy
      • Neurogenic Atrophy
  • Treatment Type
    • Medications
    • Physical Therapy
      • Ultrasound Therapy
      • Electric Simulation
    • Nutritional Therapy
    • Surgery
    • Gene Therapy
    • Others (Occupational Therapy, Respiratory Therapy, Assistive Devices, etc.)
  • End-user
    • Hospitals
    • Rehab Centers
    • Specialty Clinics
    • Others (Homecare, etc.)
  • Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa

Place an Order Copy of Muscle Wasting Disorders Market Report at:  https://www.transparencymarketresearch.com/checkout.php?rep_id=39452&ltype=S

More Trending Report by Transparency Market Research:

Allogeneic Stem Cell Market - The global industry was valued at US$ 941.8 Mn in 2022; It is projected to grow at a CAGR of 6.3% from 2023 to 2031 and reach more than US$ 1.6 Bn by the end of 2031

Liposome Drug Delivery Market - The global industry was valued at US$ 4.7 Bn in 2022; It is projected to grow at a CAGR of 8.5% from 2023 to 2031 and reach more than US$ 10.0 Bn by the end of 2031

Empty Capsules Market - The global industry was valued at US$ 2.9 Bn in 2022; It is projected to grow at a CAGR of 7.7% from 2023 to 2031 and reach more than US$ 5.6 Bn by the end of 2031

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com   
Blog: https://tmrblog.com   
Email: [email protected]

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

SOURCE Transparency Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.